Video

Dr. Zelenetz on Progress Made in MCL Treatment

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses progress made in mantle cell lymphoma (MCL) treatment.

MCL is a relatively rare disease, says Zelenetz. The typical oncologist in the United States who specializes in lymphoma will see a new diagnosis of MCL every 1 to 2 years; it is an uncommon disease with only about 4,000 cases per year reported in the United States. As a result, advances in lymphoma treatment have lagged behind that of other cancers.

However, important drugs have been approved in this space, Zelenetz adds. Several years ago, bortezomib (Velcade) was approved for the treatment of patients with relapsed/refractory MCL. The agent has activity, but because of the treatment-emergent neuropathy that has been reported, it is not widely used. Lenalidomide (Revlimid) also received regulatory approval for use in these patients, and when used in combination with rituximab (Rituxan), it is highly active, concludes Zelenetz.

Related Videos
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Tycel Phillips, MD, MPH
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer